This site uses cookies to store information on your computer. Learn more x

Consensus Figures

A number of international financial analysts cover DSM. The most recent consensus figures – provided by Vara Research – are detailed below. The figures are based on the estimates given by the banks that were approached by Vara Research.

Analysts' consensus Q4 2018, FY 2018 and FY 2019 as at 15 January 2019

  Q4 2017 Q4 2018 E FY 2018 E FY 2019 E
Sales (continuing)        
Number of Estimates   19 19 20
Highest   2,269 9,328 9,462
Consensus 2,176 2,195 9,254 9,206
Median   2,199 9,258 9,224
Lowest   2,126 9,185 8,610
adj. EBITDA (continuing)        
Number of Estimates   19 19 20
Highest   373 1,825 1,674
Consensus 359 359 1,811 1,610
Median   361 1,813 1,624
Lowest   343 1,795 1,501
of which estimated adj. EBITDA from "Temporary Vitamin Effect"        
Number of Estimates   19 19 0
Highest   10 300 -
Consensus 15 1 291 -
Median   0 290 -
Lowest   0 290 -
Underlying business,  adj. EBITDA        
Number of Estimates   19 19 20
Highest   373 1,535 1,674
Consensus 344 359 1,521 1,610
Median   361 1,523 1,624
Lowest   334 1,496 1,501
adj. EBIT (continuing)        
Number of Estimates   18 18 19
Highest   289 1,389 1,182
Consensus 240 237 1,337 1,124
Median   239 1,339 1,138
Lowest   177 1,277 1,030
Nutrition, Sales        
Number of Estimates   17 17 18
Highest   1,495 6,188 6,236
Consensus 1,428 1,435 6,128 6,030
Median   1,447 6,140 6,033
Lowest   1,326 6,019 5,488
Nutrition, adj. EBITDA        
Number of Estimates   17 17 19
Highest   276 1,413 1,285
Consensus 267 265 1,402 1,199
Median   267 1,404 1,193
Lowest   228 1,365 1,162
of which adj. EBITDA from "Temporary Vitamin Effect"        
Number of Estimates   18 18 0
Highest   10 300 -
Consensus 15 1 291 -
Median   0 290 -
Lowest   0 290 -
Nutrition underlying,  adj. EBITDA        
Number of Estimates   17 17 19
Highest   276 1,123 1,285
Consensus 252 265 1,112 1,199
Median   267 1,114 1,193
Lowest   218 1,065 1,162
Nutrition, adj. EBIT        
Number of Estimates   14 14 15
Highest   213 1,131 973
Consensus 195 195 1,113 905
Median   196 1,114 899
Lowest   157 1,075 862
Materials, Sales        
Number of Estimates   17 17 18
Highest   737 2,952 3,116
Consensus 693 698 2,913 2,972
Median   696 2,911 2,983
Lowest   669 2,884 2,848
Materials, adj. EBITDA        
Number of Estimates   17 17 19
Highest   129 522 561
Consensus 119 116 509 513
Median   117 510 512
Lowest   103 496 449
Materials, adj. EBIT        
Number of Estimates   14 14 15
Highest   96 394 439
Consensus 86 85 383 388
Median   86 384 386
Lowest   70 368 346
Innovation Center, Sales        
Number of Estimates   16 16 17
Highest   68 186 204
Consensus 43 47 165 176
Median   44 163 174
Lowest   40 158 156
Innovation Center, adj. EBITDA        
Number of Estimates   16 16 18
Highest   7 8 26
Consensus 4 4 5 12
Median   6 7 10
Lowest   -1 0 4
Innovation Center, adj. EBIT        
Number of Estimates   14 14 15
Highest   1 -15 -4
Consensus -1 -5 -21 -16
Median   -4 -20 -16
Lowest   -24 -40 -32
Corporate Activities, Sales        
Number of Estimates   16 16 17
Highest   29 62 80
Consensus 12 16 49 55
Median   13 46 50
Lowest   11 44 44
Corporate Activities, adj. EBITDA        
Number of Estimates   16 16 18
Highest   -3 -82 -83
Consensus -31 -26 -105 -108
Median   -27 -106 -109
Lowest   -31 -110 -120
Corporate Activities, adj. EBIT        
Number of Estimates   14 14 15
Highest   -21 -121 -122
Consensus -40 -36 -136 -141
Median   -36 -136 -140
Lowest   -44 -144 -158
Profit for the period, before exceptional items - Cont. Ops.        
Number of Estimates   15 15 15
Highest   281 1133 970
Consensus 202 183 1033 867
Median   180 1030 849
Lowest   127 979 819
Net EPS before exceptional items - Cont. Ops.        
Number of Estimates   15 15 15
Highest   1.63 6.48 5.52
Consensus 1.11 1.07 5.91 4.90
Median   1.00 5.87 4.82
Lowest   0.72 5.57 4.60

Related links

Disclaimer
Consensus earnings estimates are based on earnings projections made by securities analysts who cover DSM. Any opinions, forecasts, estimates, projections or predictions regarding DSM’s performance made by the analysts (and, therefore, the Consensus estimate numbers) are theirs alone and do not represent the opinions, forecasts, estimates, projections or predictions of DSM or its management. DSM does not by providing these estimates imply its endorsement of or concurrence with such information, conclusions or recommendations. DSM assumes no liability for the accuracy of such estimates and undertakes no obligation to update or revise such estimates.